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RESEARCH ARTICLE
Service users’ and carers’ views 
on research towards stratified medicine 
in psychiatry: a qualitative study
Diana Rose1*, Constantina Papoulias1, James MacCabe2 and Jennifer Walke1
Abstract 
Background: Approximately 30 % of people with a diagnosis of schizophrenia receive little to no benefit from cur-
rent medications. There is therefore an urgent need to develop more precisely targeted and effective treatments. 
Identifying biomarkers to predict response to treatment and stratify patients into groups may be a way forward. 
However, we know little about service users’ and carers’ attitudes regarding such a ‘stratified medicine’ approach for 
psychiatry—nor how this might impact on their willingness to participate in stratified medicine research. This paper 
presents psychiatric service user and carer views on research to develop stratified medicine for treatment resistant 
schizophrenia, and explores the conditions under which people would be prepared to participate in a trial and their 
willingness to undergo various research procedures.
Methods: Participatory methods were used throughout. A consultation was undertaken with an existing Service 
User Advisory Group (SUAG) in order to establish a topic guide. Service user focus groups were then conducted by 
service user researchers in Manchester, London and Edinburgh (totalling 18 people) and one carer focus group in Lon-
don, attended by eight participants. Focus groups were digitally recorded, the transcripts analysed in NVivo 10 using a 
simple thematic analysis, and quotations de-identified to protect participants.
Results: The data reflected enthusiasm for the potential of stratified medicine and both service users and carers 
demonstrated a strong desire to help others. However, some service users and carers feared poor performance on 
neuropsychological assessments, and reported that certain medication side effects might discourage them from 
undergoing procedures demanding immobility and concentration. Concerns were voiced that stratified medicine 
could encourage an overemphasis on biological symptoms, at the expense of psychosocial factors and subjective 
experience.
Conclusions: People with experience of treatment resistant schizophrenia would welcome stratified medicine 
research; however researchers should take into account how such experience might inflect service users’ willingness 
to undergo various procedures in the context of this research. These results reinforce the value of service user per-
spectives in the development and evaluation of novel treatment approaches.
Keywords: Service user research, Stratified medicine, Barriers to participation, Biomarkers, Antipsychotics, 
Schizophrenia, Qualitative methods, Focus groups, Carers
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Stratified medicine is an approach to medical diagnosis 
that makes use of biological indicators or biomarkers to 
enable a division of a particular diagnostic group into 
subgroups (or strata) on the basis of prognosis and like-
lihood that they benefit from a particular treatment. 
Stratified medicine therefore is a step towards more tai-
lored treatments or so-called ‘precision medicine’ [1]. 
There has been considerable support for this approach 
in physical medicine, notably oncology, where the drug 
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Herceptin (trastuzumab) has been shown to improve 
outcomes for women with breast cancer, only in cases 
where the tumour has a particular genotype [2]. Current 
advances in imaging technologies and in data aggregation 
are making it possible to pursue the stratification of prog-
nosis and treatment in a number of other fields, such as 
neurology, where the evidence base for particular treat-
ments has been poor [3].
In this context there is growing research interest in 
the development of stratified medicine for psychiatry, 
a field where the biological underpinnings of illness are 
not currently well understood. Here, it is hoped that the 
increased diagnostic precision associated with stratifica-
tion would help alleviate the considerable individual suf-
fering and public health costs resulting from mental ill 
health [4]. Diagnostic precision is particularly pressing in 
the case of psychosis spectrum disorders: approximately 
20–30 % of people with a diagnosis of schizophrenia do 
not respond to initial medication treatment, while in a 
significant proportion of cases treatment resistance per-
sists for a number of years [5]. Furthermore, recent stud-
ies suggest that for a significant number of service users, 
reduction or discontinuation of medication after first 
episode psychosis does not lead to increase in relapse 
rates and may facilitate recovery [6], while a number of 
service users may achieve recovery through psychosocial 
interventions alone [7]. These findings testify to a press-
ing need for a stronger evidence base for treatment in 
this area, as the currently used symptom-based nosologi-
cal categories may be bringing together heterogeneous 
types under a single diagnostic heading [7]. It is therefore 
proposed that stratified medicine research would refine 
this nosological picture by using biomarkers to identify 
homogeneous subgroups within or across present diag-
nostic categories. The reference to biomarkers may not 
be entirely accurate here, as cognitive tests—i.e. psycho-
logical markers—may prove more effective in stratifying 
populations in the context of psychiatric nosologies [8].
While researchers evince considerable enthusiasm 
for the potential of stratified medicine in psychiatry, we 
know little about service user levels of understanding 
and perceptions of stratification and of individuals’ will-
ingness to participate in related trials. Similarly, while 
the literature on barriers and facilitators to participation 
in mental health research is currently gaining ground 
[9–12], evidence is scarce on how the context of strati-
fied medicine research might impact on these. Surveys 
investigating public attitudes around stratification have 
not included mental health conditions [13, 14]. There are 
indications that service users may be ambivalent towards 
current biological accounts of mental illness and related 
pharmacological treatments [15] and that they may 
perceive the use of biomarkers in psychiatry to be stig-
matising [16, 17] but this does not necessarily predict 
inclination to participate—or not—in stratified medicine 
research.
Against this background, this paper reports on a ser-
vice user led qualitative study, which elicited psychiatric 
service users’ and carers’ perspectives on the value of 
stratified medicine for treatment resistant schizophrenia. 
This study was conducted to assist protocol design of a 
large stratified medicine research programme for treat-
ment resistant schizophrenia in the United Kingdom. 
The programme aimed to use psychological, genetic 
and neuroimaging data to define biomarkers for patient 
populations who do not respond to currently available 
dopaminergic antipsychotics. The programme objec-
tive would be to test the hypothesis that such popula-
tions might show abnormalities in glutamate, rather than 
dopamine, pathways [18, 19] and may therefore benefit 
from glutamatergic medications under development. In 
this context, our qualitative study elicited service users’ 
and carers’ responses on the acceptability of various pro-
cedures involved in the proposed research programme 
and their views on the likelihood of participating in such 
a programme.
Our study thus worked to embed service user involve-
ment in the design of stratified medicine research with 
the aim of improving acceptability and reach of such 
studies [20]. While service user involvement has gained 
considerable ground in health services research, its suit-
ability for earlier phases of the ‘translational pipeline’ is 
contested [21]. However, there is growing evidence of 
the benefits of such involvement: for example service 
users’ experiential knowledge can improve the quality of 
research by introducing new, or refining existing research 
questions [21, 22], by increasing the likelihood of recruit-
ment to target [23] and by improving consent processes 
[24]. Indeed, Callard, Rose and Wykes have recently 
called for substantive service user and public involve-
ment in early phases of ‘bench to bedside’ or translational 
research. Such early involvement, they claim, is impor-
tant because it is at the level of basic research that deci-
sions about research priorities, funding allocations and 
ultimately the goals of prognosis and treatment are being 
shaped [25].
Methods
Study design
This was a two-phase qualitative study, employing par-
ticipatory methods: it used an adapted version of the 
model developed at the Service User Research Enter-
prise (SURE) of the Institute of Psychiatry, Psychology 
and Neuroscience (IoPPN) in London. SURE conducts 
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research from the service user perspective and employs 
service user researchers throughout [15]. For this study, 
a consultation was undertaken with an existing Service 
User Advisory Group (SUAG), which advises primar-
ily, but not only, on studies at the Biomedical Research 
Centre for Mental Health (BRC) at the South London 
and Maudsley NHS Foundation Trust and the IoPPN. 
Secondly, focus groups were conducted by service user 
researchers with three sets of service users and one group 
of carers.
Study sites
The consultation with the SUAG took place in London. 
Focus groups were held at locations in London, Man-
chester, and Edinburgh.
Study population and sampling framework
Some, but not all, of the SUAG had diagnoses of treat-
ment-resistant schizophrenia. The focus groups with ser-
vice users (n =  18) took place in Mental Health Trusts 
in London, Manchester and Edinburgh and purposive 
sampling was used. All participants had a diagnosis of 
treatment-resistant schizophrenia but differed slightly on 
other parameters. The London focus group was recruited 
via the Mental Health Research network (MHRN) and 
diagnosis was the key inclusion criterion. Members of 
the Manchester group were living in a supported hous-
ing project and knew each other well. The Edinburgh 
group was recruited through the Scottish Mental Health 
Network (SMHRN) and comprised service users with a 
strong interest in research. Carers (n = 8) were recruited 
from a psychosis unit in a London Mental Health Trust. 
All were parents of people who had been treated there 
and they, too, were familiar with one another.
Study period
Consultation took place with the SUAG in April 2013; 
data were collected from the four focus groups in May–
June 2013, and analysis was conducted in late 2013 to 
early 2014.
Data collection
A topic guide was constructed by two service user 
researchers from the Service User Research Enterprise 
at King’s College London (DR and CP), together with an 
academic clinician from the main study (JM). This guide 
was specifically tailored to the needs of the proposal for 
the larger project while also incorporating findings and 
suggestions from the consultation with the SUAG. The 
two service user researchers then facilitated focus groups 
using the topic guide. Focus group participants were 
presented with a brief account of the proposed stratified 
medicine programme. They were told that:
  • stratified medicine meant developing clinical tests to 
distinguish which patients are more likely to benefit 
from a particular treatment;
  • in the treatment of schizophrenia, this approach 
would involve investigating potential brain abnor-
malities in people who do not respond to current 
anti-psychotic medications;
  • since these medications target dopamine pathways in 
the brain, people who do not respond to these may 
have abnormalities in different pathways;
  • there are indications that glutamate pathways may be 
involved instead.
Written informed consent was obtained from all par-
ticipants. Following this, the group discussion was 
structured into three topics. Firstly, facilitators invited 
participants’ views on stratified medicine as an approach 
to treatment of schizophrenia. Secondly, participants 
were asked about their attitudes towards procedures that 
might help stratify people with a diagnosis of schizophre-
nia. These procedures were presented in increasing levels 
of ‘intrusiveness’ as judged by the research team in the 
proposed study [neuropsychological tests, blood tests, 
magnetic resonance spectroscopy (MRS) and positron 
emission tomography (PET) scans]. Thirdly, participants 
were asked about their willingness to participate in a trial 
and their views on ways of promoting participation.
Discussions were audio recorded and transcribed with 
the informed consent of all participants. Transcripts were 
de-identified to protect the identity of participants.
Data analysis
Two service user researchers (CP and JW) conducted a 
deductive thematic analysis using the topic guide [26]. 
Transcripts were also analysed inductively and supple-
mentary codes identified until thematic saturation was 
reached [27]. These codes were then aggregated into 
super-ordinate themes and the coding frame was itera-
tively adjusted. NVivo10 software was used to store, 
index and retrieve textual material and to identify illus-
trative quotations.
Ethical considerations
Ethical Approval was given by the NRES Committee 
North East—Newcastle and North Tyneside 2, reference 
number 13/NE/0103.
Results
It is important to note that the focus group discussions 
were non-linear, and medication side-effects were an on-
going theme throughout the transcripts rather than being 
confined to the section of the topic guide specific to this. 
We present central findings from each of the three topics.
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‘Geared up for your body’: views on stratified medicine 
as compared to current approaches
Both service user and carer participants reported endur-
ing a very lengthy process of ‘trial and error’ with their 
medication. As a result, several service users had become 
disillusioned about the potential of existing medications 
to alleviate their symptoms: they reported feeling inca-
pacitated both by adverse effects and by the frequent 
experiences of withdrawal which are a part of regime 
change:
It takes so long for the drugs to work in your system 
and you’ve got to come off that one, and then put on 
another dose. And then it kicks in and that wouldn’t 
work so it’s up and down all the time. (Service user)
So when you have to go, [to] your assessments yeah? 
They ask how you’re feeling, well, still hearing the 
voices, medication don’t work apart from side effects, 
where do we go from here? And you’re stumped, keep 
trying, keep taking the medication and we’ll get back 
to you. They never do because there is nothing they 
can do. (Service User)
Against this shared background of disillusionment, 
proliferating side effects and ineffective treatments, when 
a particular medication proved capable of alleviating 
symptoms, it was greeted with particular enthusiasm and 
could be imbued with a life altering significance:
It made me, sort of more like me…. D’you know what 
I mean? I wasn’t a robot.
[It took] ten years to find, to put me on that. And 
when I went on Olanzapine -that had just come out- 
and they said you know this is a brand new drug it’s 
only come out, we’ll try it on you to see how it goes. 
So I tried that, totally different. (Service User)
And Clozapine worked but she was very sleepy […] 
and with great difficulty, I persuaded her psychia-
trist to prescribe [Aripiprazole] for her. And that has 
been brilliant …. she’s now awake for a full day a lot 
of the time. But it has taken a long time […] at least 
sixteen years. (Carer)
In this context, participants were broadly enthusias-
tic about an approach which held open the possibility 
of more precisely targeted treatments for themselves or 
their relatives. It is worth noting that participants did not 
use the phrase ‘stratified medicine’ in their discussions 
of that approach. Instead, they noted the heterogeneity 
of experiences between patients sharing a diagnosis and 
emphasised a need for a more individualised approach, 
sometimes drawing analogies with other healthcare 
domains and using tailoring metaphors
There’s different forms of schizophrenia, not every-
body’s going to have the same symptoms. But if you 
get given a tablet… everybody gets the same thing 
most of the time to start with. There’s no sort of indi-
viduality regarding the meds, but if you can get one 
that’s geared up for your body and how it suits your 
mind then yeah, I’m all for it, totally! (Service user)
It sounds sensible because the previous system is a 
bit like going to the opticians and handing you a box 
of glasses and saying ‘try them and come back in a 
week and see if you can see anything’ so I think it’s 
wonderful. (Carer)
[it would be like both of us] going to a shop, getting 
the exact same dress, yeah? I’d need mine a different 
size, erm, and we’d both need different alterations, 
yeah? Our bodies aren’t the same, they don’t work 
the same, erm, if we could make it …actually tailor 
make medicine for people, I think there’s only one 
thing you say, and that’s get on with it! (Service user)
Additionally, some participants suggested that the 
development of more finely honed medications may 
not in itself be sufficient to improve the lives of people 
with a diagnosis of schizophrenia. Rather, medications 
may form part of a more complex picture, a ‘jigsaw puz-
zle’, in which social contact and peer support are also 
paramount:
You need a holistic approach… okay, you need the 
meds, but you also need somebody to talk to about 
your illness, how it’s going to affect you, how it’s 
affecting other people (Service user)
You actually need lots of different things, you’re a 
jigsaw puzzle. […] sometimes you do need medica-
tions, sometimes you need a rest from medications 
because your body is screaming out, saying, no more! 
…sometimes I don’t want [an] antidepressant, I 
want a human being to sit and tell my problems to! 
(Service user)
Attitudes towards, and perceived intrusiveness of different 
procedures
Neuropsychological testing
Overall, service users were familiar with neuropsycholog-
ical assessments, having undergone several in the course 
of their treatment. For some, that familiarity meant they 
would agree to participate in trials involving such tests. 
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Others were more hesitant, reporting that they had found 
such procedures mentally challenging:
Well you see I done one, was it last year? […] we had 
an interview, and then we went and done puzzles 
[…] and I see nothing wrong with that, if it it’s gonna 
help, really I don’t. (Service User)
I could read the instructions and follow the instruc-
tions and sort of answer the questions. But when it 
came to doing like puzzles and things it was quite 
difficult… I can’t do those at all. (Service user)
Some carers were also hesitant, as they appeared con-
cerned with how their relative would cope with this kind 
of testing, They indicated that their relatives were no 
longer ‘well enough’ to submit to psychological testing. 
Some felt that such tests demanded a higher level of cog-
nitive and co-ordination skills than their relatives could 
master or tolerate—in part because of the debilitating 
effects of their medication.
[She] wouldn’t have been able to co-operate in tests 
like that at all. She wouldn’t have had the staying 
power or the co-ordination to do anything because of 
the other drugs she had been taking. (Carer)
I think the problem is with that kind of a test, I 
don’t know how it would go for anybody else, but 
my daughter when medication was first being intro-
duced would never have been well enough to do that 
kind of test. You know things had got well beyond her 
being able to sit and, you know, make a contribu-
tion like that. It kind of needs to come earlier to have 
the confidence when things are first beginning to go 
wrong. (Carer)
Blood tests
Most participants regarded blood tests as routine and 
unthreatening, a familiar and necessary component of 
their or their relative’s usual treatment regime.
Well with the medication you’re actually on they 
have to do blood tests every so often…and I think 
most of us have had that many blood tests like, it’s 
just normal! (Service user)
My son regularly, every month, he has to have 
a blood test so it would be nothing new for him. 
(Carer)
A number of service users objected to this procedure, 
on the grounds of needle phobia or known physical prob-
lems with drawing blood. Despite these concerns, blood 
testing was more readily accepted and justified by service 
users than the other test types proposed.
I’m scared of needles but if it would help my mind, I 
would yeah, but the other one [PET scan] sounds like 
needles in both arms and drips and it lasts for a few 
hours. (Service user)
I’m not particularly happy with them because I 
haven’t got any veins and it’s very difficult… A bit 
too intrusive and they hurt. (Service user)
Magnetic resonance spectroscopy (MRS)
The testing duration and enclosed space of an MRS scan-
ner proved more challenging for both service users and 
carers, who spoke of having difficulty sitting still and 
experiencing anxiety around small spaces. Here again, 
carers appeared concerned that their relatives may not be 
well enough to undergo such procedures:
The only issue I’ve got with that is sitting in a 
machine for two to three hours… that’s a hell of a 
long time. (Service user)
Being big in them means I feel trapped if it had 
been an accident or something went wrong with 
the machine I’d feel that, to get my bulk out of that 
machine and get everything that the nurse is telling 
me would just be so uncomfortable. (Service user)
I think though that with a scan like that, the person 
would have to be quite well to undergo it. I think 
that somebody who was having anxiety or anything 
like that would find it extremely difficult to be put 
into a tube and I think that would be very difficult. 
(Carer)
Additionally, some carers suggested that a scanner that 
is too small may be psychologically challenging to people 
who have experienced considerable weight gain through 
treatment:
I could see that [relative’s name] … when she was 
very big, would’ve felt uncomfortable going in there 
and if she’d not fitted; it would’ve been something 
else that would’ve not been good for her, to have not 
fitted in the tube. (Carer)
Positron emission tomography (PET) scans
All participants considered PET scans to be a particularly 
intrusive investigation, with their inherent demands on 
time and patience compounded by fear of needles and 
radioactive tracers.
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You’re still talking about 2-3  h of being pricked and 
prodded and cameras clicking on you. It’s just a 
nightmare. You wouldn’t expect that under normal 
circumstances… So the thought of lying dormant for 
two to three hours, while people are taking blood and 
giving you radioactive doses of whatever, and being 
scanned at the same time, that’s hard work. They’d 
[be] better off sedating you and doing it. (Service user)
However, this stance was countered by one service user, 
who believed that the intrusiveness of a procedure was a 
sign of its rigour and scientific authority, and therefore of 
its potential usefulness
It sounds rather too extreme. And usually for medi-
cine I think if things are that extreme, that means it 
going somewhere and it makes it easier to find out or 
to get rid of or find out what they’re trying to find out 
about my, my mental state so… it must be a hopeful 
thing to do. (Service user)
Again, some carers were doubtful whether their family 
member would be well enough to undergo this process.
I think he’d sit still for that time but whether he’d 
consent to it once again is difficult to say…one day 
he’s a different person to another. (Carer)
Willingness to participate in a trial and suggestions 
for promoting participation
Despite the aforementioned concerns, when partici-
pants were explicitly asked whether they or their relatives 
would choose to take part in trials, most confirmed that 
they would. These participants were largely motivated by 
the hope that others would not have to endure distressing 
and ineffective treatments in the future:
I would take part. Despite the inconvenience […] I 
would take part, coz I would see it as something – 
I’d obviously not benefit from it now – it would help 
other people in the future. And so long as there’s not 
gonna be any harm to myself by doing it, I would 
agree to take part (Service user)
… I would do it in the respect that it’s gonna help 
people in the future, [not to go] through the processes 
that we’ve been through; I would do it for that. (Ser-
vice User)
I think at the moment she’s so well that I don’t think 
it would unbalance her and knowing, and she’s 
always been very keen on medical things and things 
like that, I think she would want to help because 
she would feel that she was helping other people by 
doing this. (Carer)
However, those service users and carers who, after such 
distressing and ineffective treatments, had found one that 
worked for them or for their relative, were more reluctant 
to take part in procedures which, they feared, might com-
promise their hard won equilibrium.
… if I definitely had to go off my meds I’m on just 
now, I’d be scared of what was to happen when I 
came off them, because it’s taken so long to get on at 
last, to get everything just perfect. You know what I 
mean? (Service user)
I would like to think she’d do perfectly well and not 
bother, but is it worth taking the risk? I mean she’s 
been so unwell in the past, she’s so well now, why on 
earth interfere with any of it? (Carer)
In this context, receiving clear information about 
the purpose of the trial and any attendant risks, as well 
as feeling that participants’ concerns were respected, 
became particularly important. A desire for (medical or 
peer-led) reassurance about the procedures and their 
outcomes was a common theme.
I’d probably want to speak to a physician before 
going inside one of those things but as long as there’s 
preliminary need for me then I think it would be 
okay. (Service user)
If they were fully informed and they realise that 
there were no consequences from it. For example 
that if you’re going to inject radioactive dye, that 
there are absolutely no consequences from that…
And also I think they would need reassurance that 
what they’re doing is actually going to benefit other 
people. (Carer)
Other participants focused on the need to alleviate 
boredom or withdrawal symptoms throughout the more 
involved testing procedures.
I’d have to listen to music, I mean I’d have to take 
that with me and just sit… I couldn’t see myself sit-
ting there with nothing for two to three hours like ‘cos 
I get fidgety. (Service user)
Just give me something I can take, put a patch on, or 
nicotine chewing gum! (Service user)
Discussion
Stratified approaches have clear implications for improv-
ing quality of life and treatment adherence in (what is 
currently regarded as) ‘drug-resistant’ schizophrenia. In 
our study we presented stratified medicine in psychia-
try as a way of determining which sub-groups of people 
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are more likely to respond to a specific treatment. We 
thereby indicated that such a development would poten-
tially curtail lengthy and ineffective treatments. In this 
context, our participants’ enthusiasm is not surprising. 
While participants did not adopt the proposed terminol-
ogy, they clearly understood that what was being pro-
posed was a treatment more closely tailored to individual 
bodily needs. Participants felt that pursuing this goal 
would be a welcome development, insofar as it promised 
to give the field of psychiatry a scientific precision that is 
currently lacking. What is more significant for the design 
of studies and the development of recruitment strate-
gies in this field is how we may identify and attend to the 
particular anxieties which may accompany this apparent 
willingness to participate in trials.
Participants voiced a number of concerns about the 
different test types required for such studies: of these, 
worries relating to lengthy or invasive procedures and 
confined spaces aligned with researchers’ judgements 
(in ordering the procedures in the focus groups) about 
which methods would be interpreted as most intrusive. 
In discussing participants’ tolerance for different proce-
dures, we had anticipated that service users and carers 
would find PET scans considerably more challenging and 
intrusive than neuropsychological tests. This is because 
the former involve physical discomfort, a considerable 
time commitment and the administration of radioac-
tive tracers. However, participants’ responses suggested 
that, in some cases, neuropsychological tests might also 
be perceived as intrusive, insofar as engaging with chal-
lenging mental tasks could be seen as destabilising. It is 
also possible that some carers’ reluctance towards neu-
ropsychological tests stemmed from a perception that 
their relatives would be evaluated during such testing, 
and a concern that a poor result on the test (partly con-
sequent to medication side-effects) might be deleterious 
for the individual’s self-esteem. This finding has consid-
erable bearing on stratification research, particularly so 
since, in psychiatry, by contrast to other clinical fields, 
neuropsychological tests are expected to play a central 
role in stratification [8]. Similar remarks about the effect 
of procedures on participants’ self-worth were voiced by 
some carers in relation to scans: they argued that those of 
their relatives who have become overweight in the course 
of treatments might find entering the constricting space 
of an MRS scanner not only physically challenging, but 
also potentially humiliating.
Taken together, these findings present us with two 
potential barriers to participation in stratification trials. 
These barriers may be particularly pronounced for peo-
ple with a diagnosis of treatment resistant schizophrenia 
who have experienced years of ineffective treatments. 
Firstly, researchers will need to take into account the 
impact of the likely adverse effects associated with 
lengthy use of anti-psychotic medications: some of these 
side-effects (in particular weight gain, poor concentra-
tion, akathisia and incontinence) may make participants 
reluctant to undergo procedures which will involve con-
stricted spaces and immobility. Secondly, some of these 
procedures might be perceived to be mentally rather than 
physically challenging and thus potentially compromising 
to service users’ sense of self-worth. While the latter find-
ing is associated mostly with carers who may have been 
over protective of their relatives, it is nevertheless impor-
tant to be mindful of the potential effect of procedures on 
participants’ self-esteem and sense of dignity.1
Additionally, our findings suggest that there might be 
reluctance to participate in stratified medicine from (1) 
people who have—after many years—found an anti-
psychotic medication that they feel is right for them; (2) 
people who are concerned that a focus on biomarkers 
precludes adequate research and therapeutic attention to 
psychosocial factors. Further research would be needed 
to probe these concerns in greater detail.
Consequently, an understanding of the history and 
experiences of people with treatment resistant schizo-
phrenia, of the impact of this history on service users’ 
concerns about undergoing potentially taxing proce-
dures, and on their attitudes on the value and effective-
ness of medical interventions should be an important 
factor in study design. To this end, early and substantive 
involvement of service users and carers in stratified med-
icine trials can greatly enhance such understanding and 
therefore expedite the progress of research in this field.
Limitations
The results of the present study are restricted by a lack 
of demographic data on focus group participants, mean-
ing it is not yet possible to examine whether gender, age, 
or other background factors shape personal opinion on 
stratified medicine or engagement with research. Fur-
thermore, it is important to remember that intention 
(e.g. to participate in stratified medicine research, or 
to imagine that a relative would participate in strati-
fied medicine research) cannot predict actual behaviour. 
Additionally, the topic guide did not invite participants’ 
views on the possible uses of samples after testing; this 
topic featured more strongly in a recent UK public survey 
of views on stratification in general medicine [13]. At the 
same time, no participant in the present study spontane-
ously mentioned this. In a qualitative study of trial par-
ticipants’ understanding of pharmacogenetic medicine, 
1 It is important to note here that our findings resulted in an alteration to 
the protocol of the stratified medicine study: the neuropsychological tests 
chosen were the briefest possible in order to reduce their potential burden 
on participants.
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service users expressed no worries that their blood sam-
ples would be held centrally [28]. One may speculate that 
mental health service users are accustomed to informa-
tion about them being shared, or that sharing of records 
is conceptualised differently from the sharing of biologi-
cal material. However, caution should be exercised in 
generalising from these results, as research on psychiatric 
patients’ views on this topic is scarce; potentially a dou-
ble-edged sword in an era where ‘big data’ are becoming 
more important.
Finally, it is important to note that questions of aetiology 
did not figure prominently in our study. Since the study 
was preparatory to a large trial, its purpose was instru-
mental (to elicit service user and carer views on research 
on stratification, in order to refine protocol design for a 
trial) rather than exploratory (to explore service user and 
carer perceptions of stratification in psychiatry).
Conclusion
Our findings suggest that both service users and carers 
show considerable enthusiasm for stratified approaches 
in the treatment of schizophrenia. Despite considerable 
anxieties about potentially invasive procedures, we can 
reasonably expect this enthusiasm to translate into will-
ingness to participate in trials, as altruistic motivation 
is strong in this area. The provision of clear informa-
tion, willingness to engage with service user needs and, 
potentially, peer support mechanisms will likely enhance 
recruitment to trials in this area. Therefore, collaborating 
with service users in the early stages of study design—for 
example, to understand in relation to which particular 
research procedures participant anxieties or concerns 
are likely to be greater—would be beneficial and may 
increase the likelihood of recruitment to target.
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